ArticleScientific reports2026
Nrf2/SLC7A11/GPX4 pathway, a potential target of oridonin in inhibiting ferroptosis during cerebral ischemia-reperfusion injury progression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in ferroptosis research in ovarian cancer: molecular mechanisms and therapeutic perspectives.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oridonin, the primary bioactive compound in Rabdosia rubescens, has garnered significant attention in recent years. The objective of the current study is to assess the anti-ferroptosis role and possible mechanism of oridonin in cerebral ischemia-reperfusion injury (CIRI). To explore the effects of oridonin on CIRI, we established two experimental models. In vivo, a rat model of middle cerebral artery occlusion/reperfusion (MCAO/R) was constructed. In vitro, a model of oxygen-glucose deprivation/reoxygenation (OGD/R) was established using PC12 cells. The administration of oridonin could effectively restore cerebral blood flow, attenuate neuronal injury and reduce infarction area in a rat model of MCAO/R. Oridonin activated Nrf2/SLC7A11/GPX4 pathway and inhibited ferroptosis both in vivo and in vitro. Silencing of Nrf2 significantly reversed the regulatory effect of oridonin on CIRI both in vivo and in vitro. Oridonin is a promising compound to exert neurorestorative effect in CIRI. Activation of Nrf2/SLC7A11/GPX4 pathway contributes to oridonin’s anti-ferroptosis effect. This pre-clinical work may offer insight into developing new mechanisms in the management of CIRI in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.